Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.48 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9216541 | 0.88 | CHRNB2 (0.50) | NPC1GNAI3GNAO1GNAI1CHRNB2 | |
| SCHEMBL11892683 | 0.88 | CHRNB2 (0.50) | NPC1GNAI3GNAO1GNAI1CHRNB2 | |
| SCHEMBL7485454 | 0.88 | GNAI3 (0.60) | NPC1GNAI3GNAO1GNAI1L3MBTL1 | |
| SCHEMBL9221110 | 0.88 | CHRNB2 (0.50) | NPC1GNAI3GNAO1GNAI1CHRNB2 | |
| SCHEMBL21766766 | 0.88 | NPC1 (0.52) | NPC1GNAI3GNAO1GNAI1CHRNB2 | |
| SCHEMBL7490420 | 0.86 | GNAI3 (0.68) | NPC1GNAI3GNAO1GNAI1L3MBTL1 | |
| SCHEMBL22147028 | 0.85 | GNAI3 (0.71) | NPC1GNAI3GNAO1GNAI1L3MBTL1 | |
| SCHEMBL8642325 | 0.85 | GNAI3 (0.71) | NPC1GNAI3GNAO1GNAI1L3MBTL1 | |
| SCHEMBL13059514 | 0.83 | GNAI3 (0.54) | NPC1GNAI3GNAO1GNAI1CHRNB2 | |
| SCHEMBL10274470 | 0.83 | NPC1 (0.74) | NPC1GNAI3GNAO1GNAI1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183184-A1 | 3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| EP-3722283-A1 | 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-10-14 | — | — | EP | disclosed |
| US-8637557-B2 | Aminothiazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20120220767-A1 | AMINOTHIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-8093231-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| WO-2011048936-A1 | AMINOTHIAZOLE DERIVATIVE | 大正製薬株式会社 (JP) | 2011-04-28 | — | — | WO | disclosed |
| EP-1489078-B1 | BENZOFURAN DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | TELIK, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7262182-B2 | Sulfonylethyl phosphorodiamidates | TELIK, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| EP-0925299-B1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6124456-A | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-09-26 | — | — | US | disclosed |
| EP-0925299-A1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998003507-A1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220767-A1 | AMINOTHIAZOLE DERIVATIVE | AKT3, AKT2, JAK1 | NPC1 1812/4885GNAI3 1902/4885GNAO1 3965/4885 |
| US-20080039429-A1 | SULFONYLETHYL PHOSPHORODIAMIDATES | MTAP, TYMP, PHOSPHO1 | NPC1 1803/4885GNAI3 1587/4885GNAO1 1546/4885 |
| US-20230183184-A1 | 3-(Carboxyethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, PKD2 | NPC1 2461/4885GNAI3 933/4885GNAO1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.